<DOC>
	<DOCNO>NCT01051544</DOCNO>
	<brief_summary>This prospective , control , randomize , open label study , aim compare FVIII/VWF concentrate FVIII concentrate 200 IU/kg daily ability induce immune tolerance Haemophilia A patient high respond inhibitor poor prognosis success .</brief_summary>
	<brief_title>Study First TIME Immunotolerance Induction Severe Hemophilia A Patients With Inhibitor High Risk Failure : Comparison With FVIII Concentrates With Without Von Willebrand Factor - RES.I.S.T . Naive</brief_title>
	<detailed_description>The presence Factor VIII ( FVIII ) inhibitor prevents FVIII infusion work properly make treatment bleed episode difficult . Having inhibitor serious life-threatening complication patient Hemophilia . The usual treatment patient FVIII inhibitor involve `` immune tolerance induction '' ( ITI ) . Immune Tolerance mean body accept infuse FVIII FVIII effective control bleeds . ITI involve give high dos FVIII regularly inhibitor disappear . This treatment always effective . The inhibitor persist 1 5 patient undergo ITI . There 2 type FVIII concentrate : FVIII concentrate derive human plasma , contain von Willebrand factor , concentrate FVIII without VWF ( recombinant plasma derive ) . Both type concentrate commonly use induce immune tolerance patient Hemophilia A. Retrospective study subject hemophilia inhibitor risk fail ITI , indicate high rate success patient treat von Willebrand contain factor VIII concentrate . It know whether addition Von Willebrand factor offer advantage achieve immune tolerance .</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>1. severe hemophilia A ( FVIII &lt; 1 % ) ; 2. male , age ; 3. high responder ( peak inhibitor level &gt; 5 BU ) ; 4. inhibitor level study enrolment ; 5. ability willingness participate study ; 6. least one follow risk factor ITI failure : peak inhibitor titer &gt; 200 BU titer ITI start &gt; 10 BU age &gt; 7 year time inhibitor occurrence ITI &gt; 2 year 7. absence high risk cardiovascular , cerebrovascular thromboembolic event deem treat clinician . 1. concomitant systemic treatment immunosuppressive drug ; 2. concomitant experimental treatment ; 3. previous ITI attempt ; 4. previous history myocardial infarction and/or cerebral stroke .</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>ITI</keyword>
	<keyword>HAEMOPHILIA A</keyword>
	<keyword>INHIBITORS</keyword>
	<keyword>VWF/FVIII Concentrates</keyword>
</DOC>